Complete Remission of Metastatic Melanoma of the Scalp Following Treatment With Nivolumab Plus Relatlimab

Melanoma is an aggressive malignancy accounting for approximately 1% of all skin cancers. The standard of care for distant melanoma of the skin is immunotherapy with PD-1 inhibitors (nivolumab) or CTLA-4 inhibitors. In March 2022, the FDA approved the combination of nivolumab with relatlimab, a lymp...

Full description

Saved in:

Bibliographic Details
Published in:	The American surgeon Vol. 90; no. 8; p. 2078
Main Authors:	McMinn, Mary E, Brister, Kelly A, Orr, W Shannon, Sheehan, Natale T, Christopher, Wade O
Format:	Journal Article
Language:	English
Published:	United States 01-08-2024
Subjects:	Antineoplastic Agents, Immunological - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Head and Neck Neoplasms - drug therapy Head and Neck Neoplasms - pathology Humans Male Melanoma - drug therapy Melanoma - pathology Melanoma - secondary Middle Aged Nivolumab - therapeutic use Remission Induction Scalp - pathology Skin Neoplasms - drug therapy Skin Neoplasms - pathology relatlimab nivolumab metastatic melanoma nivolumab plus relatlimab
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Melanoma is an aggressive malignancy accounting for approximately 1% of all skin cancers. The standard of care for distant melanoma of the skin is immunotherapy with PD-1 inhibitors (nivolumab) or CTLA-4 inhibitors. In March 2022, the FDA approved the combination of nivolumab with relatlimab, a lymphocyte-activation gene 3 antibody. There are few reports on the efficacy of treating widespread multivisceral metastatic melanoma with nivolumab plus relatlimab with a complete clinical response. We describe the diagnosis and management of a patient with metastatic nodular melanoma treated with palliative resection of the primary tumor followed by immunotherapy with nivolumab and relatlimab. Four months after his first treatment, he had no evidence of disease on PET scan. He continued to show no evidence of disease at recent follow-up. Treatment of metastatic melanoma of the skin with nivolumab and relatlimab is an effective approach showing greater benefit to patients than nivolumab alone.
ISSN:	1555-9823
DOI:	10.1177/00031348241241642